The invention discloses application of
piperlongumine in treating and preventing
lung injury, and belongs to the technical field of medicines. Aiming at the technical bottlenecks of limited treatment means and high
case fatality rate of the existing acute
lung injury (ALI) /
acute respiratory distress syndrome (
ARDS), the invention discovers that
piperlongumine can specifically inhibit cGAS-STING
signal channel activation for the first time, and expression release of
inflammatory factors IFN-beta, IL-6 and TNF-alpha is reduced by regulating
phosphorylation of a downstream
interferon regulatory factor 3 (IRF3). In-vitro experiments prove that
piperlongumine inhibits ISD-induced
inflammatory response in a
dose-
dependent manner, and in-vivo experiments show that piperlongumine can significantly relieve LPS-induced mouse acute
lung tissue
inflammatory cell infiltration, reduce serum IL-6 and TNF-alpha levels, and improve
lung tissue pathological injury. According to the invention, the medicinal application of piperlongumine is expanded, a new
lung injury treatment scheme based on natural active compounds is provided, and the piperlongumine can be widely applied to prevention and treatment of acute
lung injury and related inflammatory lung diseases.